Veracyte Inc. has appointed Marie-Claire Taine, Ph.D., as general manager of its In Vitro Diagnostics (IVD) Business Unit, based in Marseille, France. She will lead the global expansion of Veracyte’s tests and will also serve as site lead for the company’s Marseille operations. 

Dr. Taine is a highly credentialed commercial operations leader with 30 years of experience in the medical device and pharmaceutical industries. She reports to CEO Marc Stapley.
 
“Dr. Taine’s extensive international management experience and commercial leadership make her the ideal person to lead the global expansion of Veracyte’s IVD test menu. She will be key to helping us achieve our vision of transforming cancer care for patients all over the world,” Stapley said.
 
Dr. Taine most recently served as vice president, Renal Care, Europe, and country sponsor, France, for Baxter International Inc., after having been president and general manager of the company’s French entity. At Baxter, she developed and managed implementation of European business plans, including Europe-wide and country-level alignment with market access and medical activities, and collaboration with the company’s European and U.S. operations. Prior to Baxter, Dr. Taine served as senior vice president of worldwide commercial operations for medical imaging company Guerbet, where she also served as president of its medical devices and French entities. She also previously served as vice president of Venous Solutions, EMEA, for Covidien, and general manager of Ultrasound Systems, France & North Africa, for Siemens Medical Solutions.
 
Dr. Taine earned her Ph.D. in medical imaging from Paris XI-Orsay University. She also earned an engineering degree from Ecole Centrale de Lyon, a diploma from Institut de Formation Superieure Biomedicale-Villejuif, and an MBA from Institut d’Etudes Politiques Paris.
 
“Veracyte has distinguished itself in the U.S., with tests that are helping physicians make better diagnostic and treatment decisions for their patients. I’m thrilled to join the talented and accomplished team at Veracyte as the company prepares to expand its impact, benefitting patients globally,” Dr. Taine stated.

In the United States, Veracyte offers its tests to physicians and their patients through its centralized laboratories. The company plans to offer select tests as in-vitro diagnostics in Europe and elsewhere so they may be performed locally by hospitals and laboratories. Veracyte currently offers the Prosigna Breast Cancer Assay as an IVD, with additional tests in development.
 
Veracyte is a global diagnostics company whose tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. Veracyte is based in South San Francisco.